Fund Vaxxinity’S Pivotal Phase 3 Ub-612 Heterologous Booster Trial To Combat Sars-Cov-2 Variants
06/04/2022 22:28
April 6 (Reuters) - Vaxxinity Inc VAXX.O :
* CEPI TO CO-FUND VAXXINITY’S PIVOTAL PHASE 3 UB-612
HETEROLOGOUS
BOOSTER TRIAL TO COMBAT SARS-COV-2 VARIANTS
* VAXXINITY INC - CEPI WILL PROVIDE UP TO $9.25M IN FUNDING
Source text for Eikon: ID:nGNX290m1v
Further company coverage: VAXX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxxinity
See all newsU.S. STOCKS ON THE MOVE-EV stocks, Salesforce, Verizon
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Q4 Net Income USD -11.392 Million
Vaxxinity Inc expected to post a loss of 10 cents a share - Earnings Preview